Aviragen Therapeutics Inc (NDAQ:AVIR) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Wednesday.

Aviragen Therapeutics (NDAQ:AVIR) opened at 0.701 on Wednesday. The company’s market capitalization is $27.09 million. The company’s 50-day moving average is $1.20 and its 200 day moving average is $1.37. Aviragen Therapeutics has a one year low of $0.65 and a one year high of $2.00.

“Aviragen Therapeutics Inc (AVIR) Stock Rating Lowered by HC Wainwright” was reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was stolen and republished in violation of US & international copyright and trademark law. The legal version of this news story can be read at http://www.dailypolitical.com/2017/02/16/aviragen-therapeutics-inc-avir-stock-rating-lowered-by-hc-wainwright.html.

Aviragen Therapeutics Company Profile

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Aviragen Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.